US equities
|
SPCX
$166.87
▲+4.98%
NVDA
$236.64
▲+1.15%
MU
$1,064.10
▼-1.00%
TSLA
$377.87
▲+1.96%
MSFT
$525.47
▲+1.53%
SNDK
$1,712.27
▼-0.45%
INTC
$117.09
▼-1.88%
META
$745.87
▲+2.44%
SPCX
$166.87
▲+4.98%
NVDA
$236.64
▲+1.15%
MU
$1,064.10
▼-1.00%
TSLA
$377.87
▲+1.96%
MSFT
$525.47
▲+1.53%
SNDK
$1,712.27
▼-0.45%
INTC
$117.09
▼-1.88%
META
$745.87
▲+2.44%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Corcept Therapeutics Incorporated - Common Stock
(NQ:
CORT
)
119.68
+3.45 (+2.97%)
Delayed Quote
Updated: 11:43 AM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Corcept Therapeutics Incorporated - Common Stock
< Previous
1
2
...
16
17
18
19
20
21
22
23
Next >
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
↗
July 29, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
↗
May 01, 2021
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name...
Via
Benzinga
Corcept Therapeutics Stock Drops After Disappointing Interim Data From Relacorilant Plus Nab-Paclitaxel Trial In Pancreatic Cancer
↗
June 22, 2021
Corcept Therapeutics Incorporated (NASDAQ: CORT) has announced preliminary results from its Phase 3 RELIANT trial of relacorilant for metastatic pancreatic cancer...
Via
Benzinga
Corcept Stops Phase 2 NASH Study With Miricorilant Due To Elevated Liver Enzymes In Patients
↗
May 07, 2021
Corcept Therapeutics Incorporated (NASDAQ: CORT) has announced interim data from the Phase 2 trial evaluating its selective cortisol modulator miricorilant in...
Via
Benzinga
Corcept Therapeutics Incorporated (CORT) Q1 2021 Earnings Call Transcript
↗
May 07, 2021
CORT earnings call for the period ending March 31, 2021.
Via
The Motley Fool
Topics
Earnings
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
↗
May 06, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
< Previous
1
2
...
16
17
18
19
20
21
22
23
Next >
